Navigation Links
US Neuropathic Pain Market Value Doubles to $5 Billion by 2018
Date:9/11/2008

New Indications and Products Offset Patent Expirations

SAN FRANCISCO, Sept. 11 /PRNewswire/ -- The U.S. market for drug treatment of major neuropathic pain (NP) conditions is currently valued at $2.6 billion, according to US Neuropathic Pain, a report released today by WWMR, Inc. Growth over the past four years has been driven largely by the successful launch of Lyrica (pregabalin) for diabetic neuropathic pain and post-herpetic neuralgia in December 2004 along with its 2007 approval for fibromyalgia, as well as the launch of Lilly's Cymbalta (duloxetine) for diabetic neuropathic pain in 2004. The additional June 2008 approval of Cymbalta for fibromyalgia will spur penetration of this prevalent condition.

Based on a decade of experience tracking and forecasting the NP Market, WWMR predicts healthy growth over the next 5 years due to penetration of the market for fibromyalgia. Two yet to be launched products, Forest Laboratories/Cypress Biosciences's antidepressant milnacipran and Schwarz Pharma's sodium ion channel antagonist/CRMP2 modulator lacosamide (Vimpat), will compete for market share as well as provide the benefit of an additional mechanism of action. Growth will slow between 2013 and 2018 as Lyrica and Cymbalta patents expire, and the fibromyalgia market penetration becomes saturated. Additional launch of novel compounds and new brands of existing drug classes will be required in order to sustain market growth.

The US neuropathic pain market consists of 4.7 million patients, and is expected to grow to more than 6.1 million patients, and be valued at $5.1 billion in 2018. With the addition of two key new indications to this report (Fibromyalgia and Neuropathic Cancer Pain) patient population estimates and projections as well as market value and projections, are available for a total of ten Neuropathic Pain Conditions (neuropathic back pain, fibromyalgia, diabetic neuropathy, neuropathic cancer pain, complex regional pain sy
'/>"/>

SOURCE WWMR, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
2. Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
3. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
4. US Facet Fixation Market to Increase by Over 60% Annually Through 2012
5. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
6. Injectable CTM Manufacturing Market Report Now Available
7. Eyeforpharmas Marketing Summit is shaping up to be the biggest event of its kind ever
8. SectorWatch.biz Issues MarketStats on Agri-Biotech Equities YGYB, GRO, SEED, MON, ADM, and BG
9. Filter Markets - Discover the Growth Segments
10. China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
11. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5
... , , , , , ... LOS ANGELES , Jan. 25 /PRNewswire-Asia/ -- ... the "Company"), is a leading manufacturer, distributor and,retailer of Chinese ... medical equipment in Northeastern,China . The Company today announced ...
... , Data Reported at the 2010 ... in Both Time to Tumor Progression and Overall Survival ... Capecitabine Arm , QUÉBEC CITY, Jan. 25 ... TSX: AEZ) (the "Company"), a late-stage drug development company ...
... devices, layers of atoms must be grown in neat, crystalline ... to develop bumps and defects a serious problem for ... the journal Science (Jan. 22, 2010), Cornell researchers ... films. Led by assistant professor of physics Itai Cohen, they ...
Cached Biology Technology:China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 2China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 3China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 4Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 2Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 3Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 4Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 5Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 6Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 7Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 8Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 9Watching crystals grow provides clues to making smoother, defect-free thin films 2
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... security consultant, Apollo Robbins for the 2015 ... Apollo Robbins will be ... , 2015, demonstrating some of his famous theft techniques ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "iPhone 5S Fingerprint ... Report" report to their offering. ... the acquisition of AuthenTec in July 2012, Apple ... 5S. It is currently the only device of ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   ... platform built for the post-password and Internet of Things ... additional seed funding. The venture round was led by ... Pantera Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey ... the new funding to expand its team and bring ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... hundreds of proteins at once and enabling new experiments that ... has been invented by a team of University of Chicago ... , the new micro-western arrays combine the specificity of the ... DNA microarrays. The technique will allow scientists to observe much ...
... to many plant species. Plants attract insect pollinators with ... to ensure fertilization and reproduction. However, female moths are ... flower,s scent, they lay their eggs on the green ... the Max Planck Institute for Chemical Ecology have now ...
... 2010) Two recent, separate publications identified regions with higher ... in California. Using data collected by the California ... including almost 10,000 autism cases from 1996-2000, investigators at ... risk for autism. Autism Speaks, the nation,s largest autism ...
Cached Biology News:Illuminating protein networks in 1 step 2Illuminating protein networks in 1 step 3Changing flowering times protect tobacco plants against insect herbivory 2Changing flowering times protect tobacco plants against insect herbivory 3Changing flowering times protect tobacco plants against insect herbivory 4Autism Speaks responds to recent publications citing autism clusters in California 2
... enables fully automated hybridization of microarrays on ... been designed to offer researchers improved reproducibility, ... perform a wide range of applications. ... 485C; denaturations of up to 99C. The ...
... Fully automated microarray slide processing ... The trend to miniaturization, automation ... technology a powerful tool with many ... settings. These applications range from gene ...
... The user-friendly Eppendorf Thermomixer R offers ... that require shaking, heating, and cooling. ... expanded its application and temperature control ... each accommodate 24 micro test tubes, ...
... Blot Kits overcome this limitation and offer ... wide range in low-density protein array (96- ... are ideal for performing reverse-phase protein arrays ... the presence of low abundant antigens. Protein ...
Biology Products: